更正：口服铁螯合剂去铁酮和地拉罗司有效性及毒性的单中心回顾性研究
Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
出版信息
PLoS One. 2019 Mar 13;14(3):e0214005. doi: 10.1371/journal.pone.0214005. eCollection 2019.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0211942.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0211942。]
相似文献
1
Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.更正：口服铁螯合剂去铁酮和地拉罗司有效性及毒性的单中心回顾性研究
PLoS One. 2019 Mar 13;14(3):e0214005. doi: 10.1371/journal.pone.0214005. eCollection 2019.
2
A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.地拉罗司与去铁酮治疗骨髓增生异常综合征患者铁过载的对比研究。
Leuk Res. 2013 Dec;37(12):1612-5. doi: 10.1016/j.leukres.2013.07.021. Epub 2013 Aug 9.
3
Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.地拉罗司和去铁酮可去除铁过载沙鼠心脏中的铁。
Transl Res. 2006 Nov;148(5):272-80. doi: 10.1016/j.trsl.2006.05.005.
4
MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.MRI 多中心前瞻性研究：地拉罗司治疗重型地中海贫血患者与去铁酮和去铁胺的对比。
Br J Haematol. 2018 Dec;183(5):783-795. doi: 10.1111/bjh.15595. Epub 2018 Oct 18.
5
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.地拉罗司用于治疗慢性贫血患者因定期输血导致的铁过载（输血性含铁血黄素沉着症）：一项系统评价与经济学评估
Health Technol Assess. 2009 Jan;13(1):iii-iv, ix-xi, 1-121. doi: 10.3310/hta13010.
6
The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin.地拉罗司和去铁酮对β-地中海贫血血红蛋白结构和功能的影响。
J Biomol Struct Dyn. 2009 Dec;27(3):319-39. doi: 10.1080/07391102.2009.10507319.
7
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.介绍更高剂量的地拉罗司：疗效更好，但不能有效去除心脏中的铁，且严重毒性风险增加。
Expert Opin Drug Saf. 2010 Jul;9(4):633-41. doi: 10.1517/14740338.2010.497138.
8
Deferasirox for managing iron overload in people with thalassaemia.地拉罗司用于治疗地中海贫血患者的铁过载。
Cochrane Database Syst Rev. 2012 Feb 15(2):CD007476. doi: 10.1002/14651858.CD007476.pub2.
9
Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients.每日交替使用地拉罗司和去铁酮疗法成功控制了无法治疗的输血依赖型地中海贫血患者的铁蓄积。
Am J Hematol. 2018 Oct;93(10):E338-E340. doi: 10.1002/ajh.25222. Epub 2018 Aug 14.
本文引用的文献
1
Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.单中心回顾性研究口服铁螯合剂地拉罗司和去铁酮的疗效和毒性。
PLoS One. 2019 Feb 27;14(2):e0211942. doi: 10.1371/journal.pone.0211942. eCollection 2019.
Zotero 插件